Photodynamic therapy using talaporfin sodium for synovial membrane from rheumatoid arthritis patients and collagen-induced arthritis rats.
We investigated the efficacy of photodynamic therapy (PDT) using talaporfin sodium as a new method of synovectomy for rheumatoid arthritis (RA). We first used RA synovial membrane (RASM) for in vitro and in vivo study. The RASM was obtained from patients with RA during total knee replacement. In the in vitro study, RA fibroblast-like synoviocytes (RASCs) obtained from the RASM were examined by fluorescent microscopy to measure the intracellular localization of talaporfin sodium. The cells were then subjected to PDT, and their viability was examined by 3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulphophenyl)-2H-tetrazolium inner salt assay. In the in vivo assay, RASM was obtained as described above, grafted onto severe combined immunodeficiency (SCID) mice and subjected to PDT. The damaged area of RASM was evaluated histologically at 1 day after PDT. Next, we performed a separate experiment using rats with collagen-induced arthritis (CIA). After intra-articular injection of talaporfin sodium, the concentration of talaporfin sodium accumulated in the CIA synovial membrane (CIASM) was compared with that in cartilage, periarticular muscle, and skin. We then performed PDT with intra-articular injection of talaporfin sodium and intra-articular irradiation. The damaged area of the CIASM was measured at 1 day after the PDT, and the articular histological and radiological changes of the ankle were observed at 56 days after the PDT. In RASM, talaporfin sodium accumulated in lysosomes in vitro, and the phototoxicity to RASCs in vitro and to RASM grafted onto SCID mice in vivo depended on the concentration of talaporfin sodium and the laser energy. In CIA rats, there was a greater accumulation of talaporfin sodium in the CIASM than in normal tissue. The CIASM was selectively damaged at 1 day after the PDT, and the bone and cartilage destruction were ameliorated at 56 days after the PDT. In conclusion, PDT using talaporfin sodium might be a new method for synovectomy in patients with RA.
Torikai
Eiji
E
Department of Orthopaedic Surgery, Hamamatsu University School of Medicine, 1-20-1 Handayama, Hamamatsu 431-3125, Japan. eiji@hama-med.ac.jp
Kageyama
Yasunori
Y
Kohno
Eiji
E
Hirano
Toru
T
Koide
Yukio
Y
Terakawa
Susumu
S
Nagano
Akira
A
D000818:Animals; D001169:Arthritis, Experimental / Q000000981:diagnostic imaging / Q000188:drug therapy* / Q000473:pathology; D001172:Arthritis, Rheumatoid / Q000000981:diagnostic imaging / Q000188:drug therapy* / Q000473:pathology; D002478:Cells, Cultured; D004396:Coloring Agents; D004195:Disease Models, Animal; D005347:Fibroblasts / Q000187:drug effects* / Q000473:pathology; D006801:Humans; D007270:Injections, Intra-Articular; D053685:Laser Therapy; D008297:Male; D051379:Mice; D016513:Mice, SCID; D017319:Photosensitizing Agents / Q000493:pharmacokinetics / Q000494:pharmacology*; D010789:Phototherapy / Q000379:methods*; D011166:Porphyrins / Q000493:pharmacokinetics / Q000494:pharmacology*; D011859:Radiography; D051381:Rats; D011917:Rats, Inbred Lew; D013583:Synovial Membrane / Q000473:pathology; D013778:Tetrazolium Salts; D013844:Thiazoles; D014183:Transplantation, Heterologous
D004396:Coloring Agents; D017319:Photosensitizing Agents; D011166:Porphyrins; D013778:Tetrazolium Salts; D013844:Thiazoles; C022616:thiazolyl blue; C053434:Talaporfin